SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.401
AS - Asia 1.620
EU - Europa 1.236
SA - Sud America 278
AF - Africa 41
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.586
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.353
SG - Singapore 620
GB - Regno Unito 355
CN - Cina 286
VN - Vietnam 231
HK - Hong Kong 216
BR - Brasile 213
FI - Finlandia 185
DE - Germania 166
SE - Svezia 138
IT - Italia 110
FR - Francia 73
RU - Federazione Russa 73
TR - Turchia 66
ID - Indonesia 38
BG - Bulgaria 31
IN - India 30
AR - Argentina 24
JP - Giappone 23
UA - Ucraina 19
IQ - Iraq 18
BD - Bangladesh 16
NL - Olanda 16
CA - Canada 15
IE - Irlanda 14
VE - Venezuela 14
MX - Messico 11
PK - Pakistan 10
ZA - Sudafrica 10
EG - Egitto 9
AT - Austria 8
KR - Corea 7
SA - Arabia Saudita 7
BE - Belgio 6
CO - Colombia 6
CH - Svizzera 5
EC - Ecuador 5
JO - Giordania 5
MA - Marocco 5
MY - Malesia 5
PH - Filippine 5
RO - Romania 5
UZ - Uzbekistan 5
AU - Australia 4
AZ - Azerbaigian 4
BZ - Belize 4
CL - Cile 4
IL - Israele 4
JM - Giamaica 4
LT - Lituania 4
LU - Lussemburgo 4
NO - Norvegia 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
PY - Paraguay 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
KE - Kenya 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
ES - Italia 2
GT - Guatemala 2
KZ - Kazakistan 2
NZ - Nuova Zelanda 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
HN - Honduras 1
IR - Iran 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
ML - Mali 1
MQ - Martinica 1
MU - Mauritius 1
MZ - Mozambico 1
NI - Nicaragua 1
PA - Panama 1
PG - Papua Nuova Guinea 1
PR - Porto Rico 1
Totale 7.579
Salva come PNG Salva come JPEG
Città #
Fairfield 712
Ashburn 473
Singapore 403
Santa Clara 399
Seattle 303
Woodbridge 292
Chandler 251
Houston 248
Cambridge 218
Wilmington 218
Hong Kong 213
Southend 210
Helsinki 174
Dearborn 117
Nyköping 106
London 98
San Jose 93
Ann Arbor 74
Beijing 60
New York 60
Izmir 58
Ho Chi Minh City 55
Hanoi 49
Council Bluffs 45
San Diego 45
Dong Ket 44
The Dalles 40
Lauterbourg 38
Jakarta 34
Munich 32
Princeton 31
Sofia 31
Bremen 30
Eugene 30
Phoenix 29
Shanghai 25
São Paulo 24
Los Angeles 22
Orem 22
Tokyo 21
Chicago 20
Modena 18
Redondo Beach 15
Milan 13
Boardman 12
Dublin 12
Falkenstein 10
Buffalo 9
Dallas 9
Frankfurt am Main 9
Jacksonville 9
Turku 9
Cairo 8
Hefei 8
Portsmouth 8
Atlanta 7
Chennai 7
Da Nang 7
Haiphong 7
Kunming 7
Moscow 7
Norwalk 7
Salt Lake City 7
Baghdad 6
Curitiba 6
Guangzhou 6
Hanover 6
Salvador 6
Seoul 6
Amsterdam 5
Criciúma 5
Denver 5
Jieyang 5
Mumbai 5
Rio de Janeiro 5
Toronto 5
Amman 4
Baku 4
Belize City 4
Brooklyn 4
Brussels 4
Dhaka 4
Düsseldorf 4
Edinburgh 4
Hounslow 4
Jinan 4
Johannesburg 4
Lahore 4
Montreal 4
Nanjing 4
Nuremberg 4
Redwood City 4
Ribeirão Preto 4
San Francisco 4
San Mateo 4
Tashkent 4
Turin 4
Vancouver 4
Vienna 4
Zhengzhou 4
Totale 5.819
Salva come PNG Salva come JPEG
Nome #
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 321
Immunotherapy for colorectal cancer: where are we heading? 318
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 298
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 295
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 276
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 274
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 273
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 269
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 267
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 263
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 261
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 256
Immunotherapeutic approaches for hepatocellular carcinoma 251
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 250
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 245
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 245
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 243
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 243
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 241
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 235
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 234
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 230
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 230
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 226
The Italian Rare Pancreatic Exocrine Cancer Initiative 223
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 222
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 209
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 201
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 181
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 176
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 123
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 103
Totale 7.682
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.890
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.890
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021301 0 0 0 0 0 0 0 0 0 112 86 103
2021/2022628 80 22 23 36 15 45 13 49 62 76 129 78
2022/2023727 87 80 40 59 105 80 16 75 86 9 46 44
2023/2024288 9 16 10 45 65 2 33 40 3 7 8 50
2024/20251.399 39 24 5 116 286 229 141 84 190 45 75 165
2025/20261.742 125 47 97 179 366 159 310 83 227 149 0 0
Totale 7.682